NextCure
NXTC
26 hedge funds and large institutions have $23M invested in NextCure in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
8% more funds holding
Funds holding: 24 → 26 (+2)
6.8% more ownership
Funds ownership: 54.13% → 60.93% (+6.8%)
15% less capital invested
Capital invested by funds: $26.9M → $23M (-$3.97M)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.72M |
| 2 |
VA
Verdad Advisers
Boston,
Massachusetts
|
+$525K |
| 3 |
SCM
Squadron Capital Management
Westmont,
Illinois
|
+$342K |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$336K |
| 5 |
Renaissance Technologies
New York
|
+$329K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Exome Asset Management
New York
|
-$605K |
| 2 |
Millennium Management
New York
|
-$185K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$160K |
| 4 |
SCM
Sio Capital Management
New York
|
-$155K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$95.1K |
NXTC Hedge Fund Activity: Q1 2026 in Review
26 of the 8,206 institutional investors tracked by Wall St. Rank reported a position in NextCure (NXTC) for Q1 2026, worth a combined $23M — down 15% from $26.9M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new NXTC positions and 4 closed out — a net gain of 3 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $1.72M. The largest seller was Exome Asset Management, cutting an estimated $605K.
- 26 institutional investors held NextCure (NXTC) as of Q1 2026, up from 24 in Q4 2025.
- Funds reported $23M of NextCure stock for Q1 2026, down 15% quarter-over-quarter.
- 7 funds opened new NextCure positions in Q1 2026 and 4 closed out, a net change of +3 holders.
- The largest NextCure buyer in Q1 2026 was Opaleye Management, an estimated $1.72M added.
- The largest NextCure seller in Q1 2026 was Exome Asset Management, an estimated $605K sold.
Based on aggregated 13F filings for Q1 2026.